Serum-Soluble ST2 (sST2) and NT-proBNP Levels in Children With Pulmonary Arterial Hypertension

Basit Öğe Kaydı
dc.authorscopusid59099785900
dc.authorscopusid11939830700
dc.authorscopusid6506553303
dc.authorscopusid57814321300
dc.authorscopusid15757198100
dc.authorscopusid57988347000
dc.authorscopusid57190845490
dc.contributor.authorDurmuş M.K.
dc.contributor.authorKarakurt C.
dc.contributor.authorTaşkapan Ç.
dc.contributor.authorÖncül M.
dc.contributor.authorElkıran Ö.
dc.contributor.authorBulut N.
dc.contributor.authorBağ H.G.
dc.date.accessioned2024-08-04T20:02:34Z
dc.date.available2024-08-04T20:02:34Z
dc.date.issued2022
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground: Soluble ST2 (sST2) is a member of the interleukin-1 receptor family and is considered a novel biomarker of inflammation, fibrosis, and cardiac stress. Additionally, sST2 is accepted by guidelines as a measure of risk stratification in patients with heart failure. Methods: Our study enrolled 53 subjects: 23 patients who were followed up for pulmonary arterial hypertension (PAH) and were prescribed different medications and 30 healthy children admitted to the pediatric cardiology outpatient clinic with chest pain or innocent murmurs as the control group. The plasma concentration of NT-proBNP was analyzed via the electrochemiluminescence method, and the sST2 level was analyzed via the ELISA method. Results: The mean age was 13.9 years (5.5–18 y) in the case group and 9.6 years (3–17 y) in the control group. The mean NT-proBNP level was significantly higher in the patient group than in the control group (763.73±2432.67 pg/mL vs 51.71± 30.08 pg/mL; P<0.01). The mean sST2 level was 1469.26±510.9 pg/mL in the patient group and 1151.30±655.99 pg/mL in the control group (P>0.05). Conclusions: Our results suggest that sST2 could be a significant indicator of right heart failure and cardiovascular mortality in children, as well as a novel biomarker of PAH. However, we found that the serum sST2 level was not as useful as the serum NT-proBNP level in this regard. Further studies with larger patient series are needed to evaluate sST2 as a biomarker in patients with PAH. © 2022, Iranian Heart Association. All rights reserved.en_US
dc.identifier.endpage51en_US
dc.identifier.issn1735-7306
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-85139128344en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage46en_US
dc.identifier.urihttps://hdl.handle.net/11616/91788
dc.identifier.volume23en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherIranian Heart Associationen_US
dc.relation.ispartofIranian Heart Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBiomarkeren_US
dc.subjectNT-proBNPen_US
dc.subjectPulmonary hypertensionen_US
dc.subjectSoluble ST2en_US
dc.titleSerum-Soluble ST2 (sST2) and NT-proBNP Levels in Children With Pulmonary Arterial Hypertensionen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu